AmCad BioMed announced on the 9th of May its continuous global market expansion efforts and development of innovative ultrasound imaging medical materials. The company has recently developed real-time AI intelligent analysis technology and completed software and hardware integration to launch a Point-of-Care Ultrasound (POCUS). The first successful shipment is imminent following a signed agreement with Nepal. Additionally, AmCad BioMed has signed a Non-Disclosure Agreement (NDA) with EchoNous, a leading U.S. POCUS manufacturer, to further negotiate cooperation and jointly explore new markets for POCUS ultrasound.
AmCad BioMed pointed out that the global POCUS ultrasound market (also known as point-of-care ultrasound or handheld ultrasound) holds promising prospects. The market size reached approximately $300 million in 2022, with an expected Compound Annual Growth Rate (CAGR) of 5.71%, projected to surpass $1 billion by 2030.
Several international companies have confirmed that physicians in rural clinics, who span multiple medical disciplines, greatly benefit from artificial intelligence assistance for real-time diagnosis. Recognizing the new market opportunities and potential, AmCad BioMed's thyroid ultrasound real-time AI interpretation system, "AnKe ThyroidDetect®," further expands product usage by integrating real-time AI intelligent analysis into software and hardware to develop handheld ultrasound devices, empowering grassroots and non-specialist physicians.
In addition to thyroid nodules, AmCad BioMed continues to research and develop AI for breast and liver ultrasound, along with software and hardware development integration. General Manager Li Yi-li stated that handheld ultrasound can assist healthcare workers in conducting rapid and accurate ultrasound examinations in various settings. Through real-time artificial intelligence-guided imaging, it assists physicians in making more timely and precise diagnoses across various medical fields, benefiting underserved areas with limited medical resources.
AmCad BioMed's handheld ultrasound, first introduced at the Arab Health Exhibition, the world's second-largest healthcare exhibition, earlier this year, garnered attention from multinational corporations and healthcare professionals. This month, the company has successfully signed agreements with Nepal, with ongoing negotiations for cooperation with manufacturers from countries such as India and Romania.
Li Yi-li, General Manager of AmCad BioMed, pointed out that handheld ultrasound technology is a development technology currently attracting considerable attention in the industry. It has overcome many traditional limitations, significantly improving convenience and aiding in accessing more clinics and telemedicine markets. With vast market potential and opportunities, the integration of AI and handheld ultrasound aims to increase the global adoption rate of AI ultrasound.
Resource (Mandarin):
